Phase I Study of Olaparib With Cisplatin Based Chemoradiotherapy in Squamous Cell Carcinoma of the Head and Neck
Status:
Withdrawn
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
The aim of this study is to find the safe dose and best dosing schedule of olaparib to give
in combination with cisplatin based chemoradiotherapy (CRT) in patients with locally advanced
head and neck cancer. The dose decided on in this part of the study will become the
recommended dose for the randomised Phase II trial.